IL232101A - Meldrum acid, barbituric acid, and pyrazolone are converted into hydroxylamine as hno donors - Google Patents
Meldrum acid, barbituric acid, and pyrazolone are converted into hydroxylamine as hno donorsInfo
- Publication number
- IL232101A IL232101A IL232101A IL23210114A IL232101A IL 232101 A IL232101 A IL 232101A IL 232101 A IL232101 A IL 232101A IL 23210114 A IL23210114 A IL 23210114A IL 232101 A IL232101 A IL 232101A
- Authority
- IL
- Israel
- Prior art keywords
- acid
- meldrum
- hydroxylamine
- derivatives substituted
- pyrazolone derivatives
- Prior art date
Links
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical group O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 title 1
- 229940083761 high-ceiling diuretics pyrazolone derivative Drugs 0.000 title 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N hydroxylamine group Chemical group NO AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 title 1
- GXHFUVWIGNLZSC-UHFFFAOYSA-N meldrum's acid Chemical compound CC1(C)OC(=O)CC(=O)O1 GXHFUVWIGNLZSC-UHFFFAOYSA-N 0.000 title 1
- JEXVQSWXXUJEMA-UHFFFAOYSA-N pyrazol-3-one Chemical group O=C1C=CN=N1 JEXVQSWXXUJEMA-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
- C07D231/20—One oxygen atom attached in position 3 or 5
- C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D231/08—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with oxygen or sulfur atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
- C07D231/46—Oxygen atom in position 3 or 5 and nitrogen atom in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/60—Three or more oxygen or sulfur atoms
- C07D239/62—Barbituric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
- C07D319/06—1,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161548036P | 2011-10-17 | 2011-10-17 | |
| PCT/US2012/060425 WO2013059194A1 (en) | 2011-10-17 | 2012-10-16 | Meldrum 's acid, barbituric acid and pyrazolone derivatives substituted with hydroxylamine as hno donors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL232101A0 IL232101A0 (en) | 2014-05-28 |
| IL232101A true IL232101A (en) | 2017-04-30 |
Family
ID=47143299
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL232101A IL232101A (en) | 2011-10-17 | 2014-04-13 | Meldrum acid, barbituric acid, and pyrazolone are converted into hydroxylamine as hno donors |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US9181213B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2776402B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6177246B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102061537B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN108409662B (cg-RX-API-DMAC7.html) |
| AU (2) | AU2013201929B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112014009282B1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2852914C (cg-RX-API-DMAC7.html) |
| HK (1) | HK1200168A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL232101A (cg-RX-API-DMAC7.html) |
| MX (1) | MX363306B (cg-RX-API-DMAC7.html) |
| SG (1) | SG11201401587QA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2013059194A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2776402B1 (en) | 2011-10-17 | 2017-07-26 | The Johns Hopkins University | Meldrum's acid, barbituric acid and pyrazolone derivatives substituted with hydroxylamine as hno donors |
| EP3427728B1 (en) | 2013-01-18 | 2021-07-07 | Cardioxyl Pharmaceuticals, Inc. | Pharmaceutical compositions comprising nitroxyl donors |
| ES2734060T3 (es) | 2014-01-17 | 2019-12-04 | Cardioxyl Pharmaceuticals Inc | Donadores de nitroxilo de N-hidroximetanosulfonamida |
| US9464061B2 (en) | 2014-05-27 | 2016-10-11 | The Johns Hopkins University | N-hydroxylamino-barbituric acid derivatives |
| WO2015183839A1 (en) | 2014-05-27 | 2015-12-03 | Cardioxyl Pharmaceuticals, Inc. | Pyrazolone derivatives as nitroxyl donors |
| EP3148983A1 (en) | 2014-05-27 | 2017-04-05 | The Johns Hopkins University | N-hydroxylamino-barbituric acid derivatives as nitroxyl donors |
| EP3313831B1 (en) | 2015-06-26 | 2021-03-10 | The Johns Hopkins University | N-substituted hydroxamic acids with carbon-based leaving groups as efficient hno donors and uses thereof |
| EP3365325A1 (en) | 2015-10-19 | 2018-08-29 | Cardioxyl Pharmaceuticals Inc. | N-hydroxylsulfonamide derivatives as nitroxyl donors |
| EP3365328A1 (en) | 2015-10-19 | 2018-08-29 | Cardioxyl Pharmaceuticals, Inc. | Pyrazolone derivatives as nitroxyl donors |
| US10913728B2 (en) | 2016-07-28 | 2021-02-09 | The Johns Hopkins University | O-substituted hydroxamic acids |
| SG11201906145YA (en) | 2017-01-03 | 2019-08-27 | Cardioxyl Pharmaceuticals Inc | Method of administering nitroxyl donating compounds |
| RS63124B1 (sr) | 2018-03-08 | 2022-05-31 | Incyte Corp | Aminopirazin diol jedinjenja kao pi3k-y inhibitori |
| WO2020010003A1 (en) | 2018-07-02 | 2020-01-09 | Incyte Corporation | AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS |
| US11912647B2 (en) | 2020-05-22 | 2024-02-27 | University Of Georgia Research Foundation, Inc. | Diversity-oriented synthesis of N,N,O-trisubstituted hydroxylamines from alcohols and amines by N—O bond formation |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3751255A (en) | 1972-03-24 | 1973-08-07 | Eastman Kodak Co | Photosensitive and thermosensitive element, composition and process |
| JPS567710A (en) | 1979-06-28 | 1981-01-27 | Sansho Seiyaku Kk | Whitening cosmetic |
| US4539321A (en) | 1981-10-26 | 1985-09-03 | William H. Rorer, Inc. | 5-Diaza-aryl-3-substituted pyridone compounds |
| EP0188040B1 (en) | 1985-01-11 | 1991-08-14 | Abbott Laboratories Limited | Slow release solid preparation |
| US4663351A (en) | 1985-08-23 | 1987-05-05 | Berlex Laboratories, Inc. | Dobutamine tri-isobutyric acid ester and the use thereof as a cardiotonic agent |
| US4798824A (en) | 1985-10-03 | 1989-01-17 | Wisconsin Alumni Research Foundation | Perfusate for the preservation of organs |
| JP2773959B2 (ja) | 1990-07-10 | 1998-07-09 | 信越化学工業株式会社 | 大腸内放出性固形製剤 |
| EP1026162A4 (en) | 1997-10-24 | 2001-01-17 | Shionogi & Co | ANTI-RHUMATISMAL AGENT |
| UA73092C2 (uk) | 1998-07-17 | 2005-06-15 | Брістол-Майерс Сквібб Компані | Таблетка з ентеросолюбільним покриттям і спосіб її приготування |
| DE69924735T2 (de) | 1998-07-28 | 2006-01-19 | Tanabe Seiyaku Co., Ltd. | Zur wirkstoffabgabe an zielorten im darm fähige zubereitung |
| GB9918684D0 (en) | 1999-08-09 | 1999-10-13 | Novartis Ag | Organic compounds |
| GB0114223D0 (en) | 2001-06-12 | 2001-08-01 | Ici Plc | Catalytic oxidation process |
| US20040038947A1 (en) * | 2002-06-14 | 2004-02-26 | The Gov. Of The U.S. Of America As Represented By The Sec. Of The Dept. Of Health & Human Services | Method of treating ischemia/reperfusion injury with nitroxyl donors |
| US6936639B2 (en) | 2002-08-21 | 2005-08-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Nitroxyl progenitors in the treatment of heart failure |
| WO2005061519A1 (en) | 2003-12-19 | 2005-07-07 | Takeda San Diego, Inc. | Kinase inhibitors |
| AU2005209843B2 (en) | 2004-01-30 | 2012-02-16 | The Johns Hopkins University | Nitroxyl progenitor compounds and methods of use |
| US8168771B2 (en) | 2005-01-31 | 2012-05-01 | The Johns Hopkins University | Use of consensus sequence as vaccine antigen to enhance recognition of virulent viral variants |
| WO2007002444A1 (en) | 2005-06-23 | 2007-01-04 | Johns Hopkins University | Thiol-sensitive positive inotropes |
| EP2596785A1 (en) * | 2006-03-17 | 2013-05-29 | Johns Hopkins University School of Medicine | N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors |
| CA2648384A1 (en) | 2006-04-13 | 2007-10-25 | Wake Forest University Health Sciences | C-nitroso-derived nitroxyl donors |
| BRPI0817562A2 (pt) | 2007-09-26 | 2017-05-02 | Cardioxyl Pharmaceuticals Inc | derivados de n-hidroxilsulfonamida como novos doadores de niltroxil fisiologicamente úteis |
| HUE030372T2 (en) | 2008-05-07 | 2017-05-29 | Cardioxyl Pharmaceuticals Inc | New nitroso compounds as nitroxyl donors and methods for their use |
| US20110160200A1 (en) | 2009-11-23 | 2011-06-30 | Cardioxyl Pharmaceuticals, Inc. | Nitroxyl Progenitors for the Treatment of Pulmonary Hypertension |
| CN105130855B (zh) * | 2009-12-07 | 2018-05-25 | 约翰斯霍普金斯大学 | 二酰基化的羟基胺衍生物及其用途 |
| JP5826762B2 (ja) | 2009-12-07 | 2015-12-02 | ザ ジョンズ ホプキンス ユニバーシティ | Ｎ−アシルオキシスルホンアミドおよびｎ−ヒドロキシ−ｎ−アシルスルホンアミド誘導体 |
| EP2776402B1 (en) | 2011-10-17 | 2017-07-26 | The Johns Hopkins University | Meldrum's acid, barbituric acid and pyrazolone derivatives substituted with hydroxylamine as hno donors |
| EP3427728B1 (en) | 2013-01-18 | 2021-07-07 | Cardioxyl Pharmaceuticals, Inc. | Pharmaceutical compositions comprising nitroxyl donors |
| US9464061B2 (en) | 2014-05-27 | 2016-10-11 | The Johns Hopkins University | N-hydroxylamino-barbituric acid derivatives |
| WO2015183839A1 (en) | 2014-05-27 | 2015-12-03 | Cardioxyl Pharmaceuticals, Inc. | Pyrazolone derivatives as nitroxyl donors |
| EP3148983A1 (en) | 2014-05-27 | 2017-04-05 | The Johns Hopkins University | N-hydroxylamino-barbituric acid derivatives as nitroxyl donors |
-
2012
- 2012-10-16 EP EP12781538.9A patent/EP2776402B1/en active Active
- 2012-10-16 SG SG11201401587QA patent/SG11201401587QA/en unknown
- 2012-10-16 MX MX2014004596A patent/MX363306B/es unknown
- 2012-10-16 WO PCT/US2012/060425 patent/WO2013059194A1/en not_active Ceased
- 2012-10-16 US US14/352,399 patent/US9181213B2/en active Active
- 2012-10-16 CA CA2852914A patent/CA2852914C/en active Active
- 2012-10-16 BR BR112014009282-6A patent/BR112014009282B1/pt not_active IP Right Cessation
- 2012-10-16 CN CN201810435608.5A patent/CN108409662B/zh not_active Expired - Fee Related
- 2012-10-16 AU AU2013201929A patent/AU2013201929B2/en not_active Ceased
- 2012-10-16 HK HK15100597.0A patent/HK1200168A1/xx unknown
- 2012-10-16 JP JP2014537151A patent/JP6177246B2/ja not_active Expired - Fee Related
- 2012-10-16 KR KR1020147013269A patent/KR102061537B1/ko not_active Expired - Fee Related
- 2012-10-16 CN CN201280051009.4A patent/CN104053647B/zh not_active Expired - Fee Related
-
2014
- 2014-04-13 IL IL232101A patent/IL232101A/en active IP Right Grant
-
2015
- 2015-10-21 AU AU2015246114A patent/AU2015246114A1/en not_active Abandoned
- 2015-10-29 US US14/927,039 patent/US9499511B2/en active Active
-
2016
- 2016-10-11 US US15/290,872 patent/US9862699B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20140275134A1 (en) | 2014-09-18 |
| MX2014004596A (es) | 2014-09-04 |
| CN104053647A (zh) | 2014-09-17 |
| US9499511B2 (en) | 2016-11-22 |
| AU2013201929B2 (en) | 2015-07-23 |
| SG11201401587QA (en) | 2014-07-30 |
| US20170050947A1 (en) | 2017-02-23 |
| CA2852914C (en) | 2019-11-26 |
| BR112014009282B1 (pt) | 2021-12-14 |
| CN104053647B (zh) | 2018-06-01 |
| HK1200168A1 (en) | 2015-07-31 |
| KR102061537B1 (ko) | 2020-01-03 |
| EP2776402A1 (en) | 2014-09-17 |
| MX363306B (es) | 2019-03-20 |
| EP2776402B1 (en) | 2017-07-26 |
| US9181213B2 (en) | 2015-11-10 |
| WO2013059194A1 (en) | 2013-04-25 |
| IL232101A0 (en) | 2014-05-28 |
| CN108409662A (zh) | 2018-08-17 |
| BR112014009282A2 (pt) | 2017-06-13 |
| AU2015246114A1 (en) | 2015-11-12 |
| KR20140107197A (ko) | 2014-09-04 |
| US9862699B2 (en) | 2018-01-09 |
| BR112014009282A8 (pt) | 2020-04-22 |
| JP6177246B2 (ja) | 2017-08-09 |
| CN108409662B (zh) | 2021-10-26 |
| JP2015501308A (ja) | 2015-01-15 |
| AU2013201929A1 (en) | 2013-05-02 |
| US20160115148A1 (en) | 2016-04-28 |
| CA2852914A1 (en) | 2013-04-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL232101A0 (en) | Meldromic acid, barbituric acid and pyrazolone derivatives are converted by hydroxylamine as hno donors | |
| AP3482A (en) | Branched 3-phenylpropionic acid derivatives and the use thereof | |
| IL257179A (en) | A preparation that includes aflibercept, folinic acid, 5-fluorouracil (5-fu) and irinotecan (pulphyry) | |
| SG2014009286A (en) | 3,5-disubstituted alkynylbenzene compound and salt thereof | |
| EP2706855A4 (en) | AQUEOUS SOLUTIONS FROM 1,2-BENZISOTHIAZOLIN-3-ON | |
| PL2934592T3 (pl) | C6-c18-acylowana pochodna kwasu hialuronowego, sposób jej wytwarzania, mieszanina nanomicelarna na jej bazie, sposób jej wytwarzania oraz sposób wytwarzania stabilizowanej mieszanki nanomicelarnej i jej zastosowanie | |
| PL2678332T3 (pl) | Pochodne diaminopirymidyny i sposoby ich wytwarzania | |
| IL250370A0 (en) | Propionic acid derivatives substituted with heteroaroylamino in position 3 and their use as pharmaceuticals | |
| IL249826A0 (en) | Propionic acid derivatives converted in 3-heteroylamino and their use in pharmaceutical preparations | |
| EP2763998A4 (en) | TRI-HETEROCYCLIC DERIVATIVES, MANUFACTURING METHOD AND USES THEREOF | |
| EP2709455A4 (en) | PROCESSES FOR THE PREPARATION OF 5-AZASPIRO [2.4] HEPTANE-6-CARBOXYLIC ACID AND ITS DERIVATIVES | |
| IL218764A (en) | Crystalline lupilopinic acid and the process for its preparation, its uses, and its pharmaceutical preparations | |
| IL240447A (en) | Propionic Acid-Baryl Acid Derivatives and Their Use as Pharmaceutical Preparations | |
| Demir | Revival of interest: the theory of EH Carr | |
| IL231096A (en) | Theses are converted into 2- (novel-6-Iloxy) and used as pharmaceutical preparations | |
| Lee et al. | Model Kits and Spatial Ability | |
| IL240422B (en) | Bi-aryl derivatives of propionic acid and their use as medicinal preparations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed |